+38 044 223 28 95
00380930552240 (باللغة العربية)
+38 044 223 28 95
Request Info

News and articles about ALS treatment

Fetal stem cells help slow down ALS progression 04 January 2016

Combined treatment of ALS including kinesiotherapy, respiratory gymnastics and administration of FSCs suspensions proved to objectively inhibit a progression of ALS

Fetal stem cell treatment improves breathing parameters in patients wirh respiratory failure 28 October 2015

As our study shows, fetal stem cell treatment improved both subjective and objective breathing parameters as early as 6 months post‐treatment in patients wirh respiratory failure.

Stem Cell Therapy for ALS Patients Moves Closer To Reality 19 July 2015

As a recently completed phase 1 clinical trial shows, stem cells can be safely applied in patients with amyotrophic lateral sclerosis (ALS).

Enhanced Adult Stem Cell Treatment Halts ALS Progression 18 October 2014

A stem cell treatment for ALS and other incurable neurodegenerative diseases gets early efficacy proofs and is entering Phase II clinical trials in the US.

All news


Amyotrophic lateral sclerosis (ALS, Charkot’s disease, Charkot’s sclerosis, in English-speaking countries – Lou Gehrig’s disease), or motor neuron disease, is a progressing illness that manifests as gradual weakening and atrophy of muscles and lasts for two to five years (in very rare cases – for seven years) with 100% fatal outcome. The clinical picture is compliant with lesion of central and peripheral motor neurons that results in bulbar syndrome as well as muscular atrophy in extremities and respiratory muscles.
Major manifestations of amyotrophic lateral sclerosis in patients include the following:
  • weakness;
  • muscle spasms;
  • disorders of speech and swallowing;
  • problems with keeping balance;
  • spasticity;
  • increased deep reflexes, or reflexogenic zone expansion;
  • pathological reflexes;
  • fibrillations;
  • atrophy;
  • hanging foot;
  • respiratory disorders;
  • paroxysms of involuntary laughter or cry;
  • depression.

Treatment of ALS with stem cells

Indications for ALS treatment with stem cells include confirmed ALS diagnosis, disease progression, and lack of response to existing treatment methods. Prior to year 2000, contraindications to treatment included respiratory failure, grade III, artificial lung ventilation, dysphagia, and presence of gastric stoma. However, nowadays Cell Therapy Center EmCell has experience of treating patients with the above-mentioned complications and disorders that allows for prolonging their life by more than five years.

After transplantation of fetal stem cells, 67% of ALS patients note diminishing weakness, improvement of appetite and mood, decrease in intensity of fasciculations and spasticity. Within two months after transplantation, increase of motion volume in extremities, decrease in muscular rigidity, normalization of reflexes, decrease in the number of fasciculation zones, better tolerability of daily chores, reduction in intensity of dysphagia and dysarthria (improvement of swallowing, articulation, and clarity in pronunciation of words) have been observed in 34% of patients. Stable positive clinical effect after treatment persists for three to six months.

About 48% of patients need to repeat the course of treatment during the year for retaining the attained positive results. In 25% of cases, patients need periodic transplantations of stem cells every 1.5–2 years. Duration of the ALS treatment course at Cell Therapy Center EmCell, as a rule, totals 2 days.

Transplantation of fetal stem cells does not combat the immediate cause of the disease (to date, the exact cause of disease has not been found); however, it exerts substantial influence on links of the pathological process and slows down disease progression. Transplantation of fetal stem cells improves the quality of life of ALS patients and their ability to work, and prolongs their life.


Experience of ALS treatment at Cell Therapy Center EmCell
Fetal stem cells in amyotrophic lateral sclerosis (poster presentation)
English, pdf, 930 kb 


Patient F.T.G., 47. Amyotrophic lateral sclerosis, cervical form, marked flaccid tetraparesis

Patient B.I., 44. ALS, with cervicothoracic involvement, marked tetraparesis, and bulbar palsy. S.p. disc surgery in 2002

Patient S.M., 68. Amyotrophic lateral sclerosis. Bulbar palsy. Spastic tetraparesis

Request additional information